Last Updated: March 2026

Medroxyprogesterone Lawsuit: Generic Depo-Provera and Meningioma Claims

Key Point

If you received generic medroxyprogesterone acetate injections instead of brand-name Depo-Provera, you may still qualify for a meningioma lawsuit. The active ingredient is identical — and so is the risk.

What Is Medroxyprogesterone Acetate?

Medroxyprogesterone acetate (MPA) is the active pharmaceutical ingredient in both brand-name Depo-Provera and its generic equivalents. It is a synthetic progestin — a lab-made version of the hormone progesterone — used primarily as an injectable contraceptive.

When your pharmacy dispenses "the generic" of Depo-Provera, you are receiving the same drug at the same dose (150mg intramuscular injection) on the same schedule (every 3 months). The only differences are the manufacturer's name and packaging.

Generic Manufacturers of Medroxyprogesterone Acetate

Teva Pharmaceuticals
Mylan (now Viatris)
Greenstone LLC (a Pfizer subsidiary)
Hikma Pharmaceuticals
Various other FDA-approved generic manufacturers

Same Drug, Same Risk: The Science

The 2024 BMJ study that found a 5.6x increased risk of meningioma was specific to the compound medroxyprogesterone acetate — not to the Depo-Provera brand name. This means:

The meningioma risk is linked to the chemical compound, not the brand
Generic medroxyprogesterone carries the same risk profile as brand-name Depo-Provera
The FDA's December 2025 label update applies to all formulations of injectable medroxyprogesterone
Claims involving generic versions are included in MDL 3140

Can You Sue If You Used the Generic?

Yes. The current litigation (MDL 3140) includes claims from women who used both brand-name Depo-Provera and generic medroxyprogesterone acetate. The legal theory — failure to warn about the meningioma risk — applies regardless of which manufacturer produced the specific injection you received.

However, there are some legal nuances worth understanding:

Brand-Name vs. Generic Liability

Under federal pharmaceutical law, generic drug manufacturers are generally required to use the same labeling as the brand-name drug. This creates a complex legal landscape:

Pfizer (brand-name manufacturer) is the primary defendant in most cases
Generic manufacturers may also face liability depending on the jurisdiction and specific facts
Your attorney will determine the appropriate defendants based on your records

How to Determine What You Received

Many women aren't sure whether they received brand-name Depo-Provera or a generic equivalent. Here's how to find out:

Pharmacy records — your pharmacy maintains records of exactly what was dispensed, including the manufacturer
Insurance claims — your explanation of benefits (EOB) statements list the specific drug dispensed
Medical records — your doctor's notes may indicate which product was administered
It may not matter — in many cases, the active ingredient is what matters for eligibility, not the specific manufacturer

Depo-Provera vs. Medroxyprogesterone: Key Comparison

Active ingredient: Both contain medroxyprogesterone acetate 150mg
Administration: Both are intramuscular injections every 3 months
FDA approval: Brand approved 1992; generics approved subsequently
Meningioma risk: Same — linked to the compound, not the brand
Lawsuit eligibility: Both qualify for MDL 3140 claims
FDA warning: Applied to all formulations in December 2025

Read our detailed comparison of brand-name vs. generic →

What You Should Do

Whether you used brand-name Depo-Provera or generic medroxyprogesterone:

Gather your records — injection history, pharmacy records, and meningioma diagnosis documentation
Check your state's deadline — statute of limitations varies by state
Get a free case evaluation — attorneys experienced in this litigation can assess your specific situation

Used Generic Medroxyprogesterone? You May Still Qualify.

Brand name or generic — the drug is the same and so are your legal options. Find out if you're eligible.

Check Your Eligibility →